

Optimal Preparation of COVID-19 Viral Transport Medium for Culture

Julie McAuley

The University of Melbourne

Claire Fraser

The University of Melbourne

Elena Paraskeva

The University of Melbourne

Elizabeth Trajcevska

The University of Melbourne

Michelle Sait

The University of Melbourne

Nancy Wang

The University of Melbourne

Eric Burt

3DMeditech

Damian Purcell

The University of Melbourne

Richard Strugnell (✉ rastru@unimelb.edu.au)

The University of Melbourne <https://orcid.org/0000-0003-0614-5641>

Short report

Keywords: SARS-CoV-2, culture, transport media, VTM, diagnosis

Posted Date: December 15th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-127019/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on March 10th, 2021. See the published version at <https://doi.org/10.1186/s12985-021-01525-z>.

Abstract

Introduction

The sudden arrival of the COVID-19 pandemic placed significant stresses on supply chains including viral transport medium (VTM). The VTM that was urgently required needed to support viral replication, as well as other routine diagnostic approaches. We describe the preparation and validation testing of VTM for rapidly expanding diagnostic testing, where the capacity of the VTM to preserve viral integrity, for culture, isolation and full sequence analysis, was maintained.

Methods

VTM was prepared using different methods of sterilization then 'spiked' with virus. The VTM was investigated using viral culture in Vero cells, and for nucleic acid detection by quantitative PCR (qPCR).

Results

The best results were obtained by filter and autoclave-based sterilization. The VTM proved robust for culture-based analyses provided the inoculated VTM was stored at 4°C, and tested within 48 hours. The filtered VTM also supported PCR-based diagnosis for at least 5 days when the mock inoculated VTM was held at room temperature (RT).

Discussion

The manual handling of VTM production, including filling and sterilization, was optimized. SARS-CoV-2 was spiked into VTM to assess different sterilization methods and measure the effects of storage time and temperature upon VTM performance. While most diagnostic protocols will not require replication competent virus, the use of high quality VTM will allow for the next phase of laboratory analysis in the COVID-19 pandemic, including drug and antibody susceptibility analysis of re-isolated SARS-CoV-2, and for the testing of vaccine escape mutants.

Key Points

- The disruption by COVID-19 to international supply chains has made importation of diagnostic reagents from traditional sources more complex, and self-reliance is becoming important
- COVID-19 diagnosis generally relies on detecting the virus through nucleic acid amplification, or antigen identification
- Though viral culture has become a 'lost art', culture will be necessary to support nucleic acid-based diagnosis with culture to resolve breakthrough infections in those vaccinated, treated or seemingly immune
- This paper examines the ability of viral transport medium to support COVID-19 viral culture

Introduction

The COVID-19 global pandemic has tested the supply chains that support the diagnosis of infections, including testing equipment and assay components and the availability of swabs and viral transport medium (VTM), in some areas, became limiting for COVID-19 testing.

The CDC has a draft Standard Operating Procedure (SOP) for the preparation of VTM (SOP#:DSR-052-04) and VTM must sustain viral integrity and suppress contaminating microorganisms that might interfere with diagnosis (1). In Australia, the Therapeutic Goods Administration requests VTM sterility and a composition consistent with the CDC SOP.

The Media Production Unit (MPU) at the Peter Doherty Institute for Infection and Immunity, a small accredited (ISO/IEC17025:2017), near at-cost, media provider for local and regional diagnostic laboratories using largely manual processes, was asked to supply VTM at 20,000 units per week. Production of VTM at the MPU expanded in parallel with the local production of 3D-printed nasopharyngeal swabs to address increased testing (2). This study analyses sterilization and VTM ability to support to the growth of SARS-CoV-2 in permissive cells.

Materials And Methods

Virus

Stocks of SARS-CoV-2 isolate hCoV-19/Australia/VIC01/2020 (3) was produced as previously described (4). The undiluted stock had a 50% Tissue Culture Infectious Dose (TCID₅₀) of 10^{5.24} TCID₅₀/mL

Media

VTM was produced according to CDC specifications, as a 3 mL volume in a 10 mL plastic, sterile tube, comprising Anderson's modified Hanks Balanced Salt Solution (8.0 g/L NaCl, 0.4 g/L KCl, 0.05 g/L Na₂HPO₄, 0.06 g/L KH₂PO₄, 1.0 g/L Glucose, 0.7 g/L NaHCO₃, 0.2 g/L MgSO₄·7H₂O, 0.14 g/L CaCl₂·2H₂O) with 2% v/v heat-inactivated fetal bovine serum (Sigma, Australian origin), 100 µg/mL gentamicin and 0.5 µg/mL amphotericin B (<https://www.cdc.gov/coronavirus/2019-ncov/downloads/Viral-Transport-Medium.pdf>). The VTM was sterilized by autoclaving (110°C for 10 minutes), unfiltered but gamma-irradiated (15 kGy), or filter-sterilized (0.2 µm). In viral infection studies, minimal essential medium (MEM) (Sigma, Mannheim, Germany) with or without 2% v/v fetal bovine serum, was used.

Antimicrobial properties of VTM prepared by different means

Bacterial or yeast stationary phase cultures were diluted and inoculated into VTM at 10³-10⁴ CFU. The VTM was incubated for 3 days at RT (18-20°C), whereafter 10 µL was removed and plated onto HBA.

Growth on HBA was compared with the inoculum and reported as no growth (NG), < 10 colonies (+), or > 300 colonies (+++).

Virus 'spiking' experiments

The 'spiking' of VTM with SARS-CoV-2 was conducted in the Doherty Institute PC3 Laboratory. Each 3 mL VTM sample (n = 3 per preparation condition) was incubated with 300 µL of SARS-CoV-2 stock (at $10^{5.25}$ TCID₅₀/mL) to yield 60,000 infectious viral particles per 3.3 mL. Samples were incubated at RT (18-19°C, 40% relative humidity) or at 4°C, for various periods before 200 µL was harvested and a TCID₅₀ performed.

50% Tissue Culture Infectious Dose assay (TCID₅₀)

Tissue culture plates (24 well) were seeded with Vero cells 24 hours prior to use and were used at ~ 95% confluency. The samples were serially diluted and inoculated (4 replicates/sample and up to 4 serial dilutions) and incubated for 45 min to enable virus infection of monolayers, then infection media (without FBS) but with TPCK trypsin (1 µg/mL) was added. The plates were incubated (37°C, 5% CO₂) and examined 3 d post-inoculation for virus-induced cytopathic effect (CPE). The TCID₅₀/mL was calculated (5) and plotted as the mean ± standard error of repeated experiments. A two-way ANOVA with Tukey post-tests and $p < 0.05$ was considered to indicate statistical significance.

Quantitative PCR assay of virus in VTM

Inactivated SARS-CoV-2 virus was inoculated into 3 mL of filtered sterilized VTM or Kang-Jian Viral transport media (catalogue no KJ502-19) and tested at day 0 then 5 days post inoculation after storage at RT or 4°C. A 300 µL sample was extracted on the Chemagic360 platform using a Chemagic Viral Nucleic Acid Kit (Perkin Elmer) and eluted into 60 µL. PCR targeting the SARS-CoV-2 E gene comprised 5 µL nucleic acid extract, 1 x qScript XLT One-Step RT-qPCR ToughMix Low ROX (Gene Target Solutions), 400 nM of primers E_Sarbeco_F and E_Sarbeco_R and 200 nM probe E_Sarbeco_P1 (6) using conditions described by Corman *et al.* 2020 (6).

Results

The antimicrobial properties of the VTMs produced by the three sterilization methods is shown in Table 1. The antifungal activity of the VTM was decreased by autoclaving or gamma irradiation, whereas the antibacterial activity was not affected by the method of preparation.

Table 1
Inhibition of bacteria and yeasts by VTM

Organism	Inoculum	Filtered	Autoclaved	γ-irradiated
<i>Streptococcus pyogenes</i>	+++	NG	NG	NG
<i>Escherichia coli</i>	+++	NG	NG	NG
<i>Staphylococcus aureus</i>	+++	NG	NG	NG
<i>Candida albicans</i>	+++	NG	+++	+++
<i>Saccharomyces cerevisiae</i>	+++	NG	+	+++

Stationary phase cultures of 3 bacteria and 2 yeasts were diluted and inoculated into VTM with concentrations between 10^3 and 10^4 bacteria or yeast, mixed and 10µl was immediately removed and plated onto horse blood agar (Inoculum). The VTM was then incubated for 3 days at RT (18-20°C) whereafter 10ul was removed and plated onto HBA. The growth on HBA was determined. No growth (NG), + <10 colonies, +++ >300.

Approximately $10^{4.8}$ TCID₅₀ SARS-CoV-2 virus was seeded into the VTM. The samples were stored at RT (18-19°C), or at 4°C for 8–72 hours. After storage, dilutions of VTM were inoculated onto 95% confluent Vero cells and CPE determined after 3 days. The TCID₅₀/mL was calculated for each sample and compared with the starting inoculum (Fig. 1). Samples stored at RT or 4°C showed relatively similar infectious viral loads over 24 hours, where after the viral load in the VTM prepared by gamma irradiation declined significantly.

Samples stored at RT revealed limited impact on recovery of replicative virus with storage over the first 24 hours. After 24 hours, there was a significant decline in recovered virus from VTM that was prepared by gamma-irradiation, and by 48 hours at RT, no replicative virus was recovered from VTM that was prepared by gamma-irradiation.

To confirm that the filtered VTM did not interfere with PCR-based diagnosis of COVID-19, inactivated SARS-CoV-2 was added to VTM (MPU or Kan-Jian (control)) and incubated for 5 days at RT, or at or 4°C, prior to qPCR testing (Table 2). The Ct values for all 6 samples, day 0 and day 5 at RT or 4°C, were within the expected ranges (27.1–28.2).

Table 2
Ability of VTM to support qPCR s

		Swab held at 4°C		Swab held at 18-20°C	
Media	Period	0 days	5 days	0 days	5 days
Kang-jian	Ct Value	ND	28.0	27.1	28.0
MPU VTM	Ct Value	ND	27.8	28.2	28.0

Quantitative PCR (qPCR) was used to analyse inactivated SARS-CoV-2 was 'spiked' into commercially source viral transport media (Kang-Jian) or VTM produced by the Media Production Unit. The transport media were held at 4°C or RT (18-20°C) for 5 days, because nucleic acid was extracted and the numbers of genomes determined by cycle threshold (Ct) number in the PCR. The values were within normal variation (i.e. one cycle, 27.5-28.5 cycles) for the amount of nucleic acid inoculated into the transport media. ND – not done.

Discussion

COVID-19 drove the parallel development of diagnostic regimes on different platforms, using assays that detect viral nucleic acid, viral proteins and antibodies induced by infection. As therapies and vaccines are introduced, it will be important to isolate infection-competent virus from diagnostic samples to test for e.g. virus 'escape mutants' to complement qPCR testing. This study explores the ability of VTM to support SARS-CoV-2 culture, produced using different sterilization options - filter sterilization, autoclave and gamma-irradiation.

The Australian Department of Health asked that VTM comply with CDC specifications (7), despite recent evidence that, for short transits, saline performs as well as VTM (8, 9) for standard qPCR-based diagnostic procedures. We expected that culture-based analysis would require greater preservation of the virus present in diagnostic samples. Although not previously a VTM provider, the MPU was asked to provide 20,000 vials of VTM per week and sought to optimize the production so as to minimize its impact on staff and ongoing media supply operations.

Gamma-irradiated VTM was less supportive of viral culture, resulting in a drop of viral titre of between 100 – 10,000-fold, 2–3 days after inoculation, which was more marked if the samples were stored at RT. After 72 hours at RT, no infectious virus was recovered from VTM prepared by gamma-irradiation. The reason why irradiation would destroy the preservative properties of VTM were not explored but irradiation can denature bovine serum proteins (10). VTM that was filter-sterilized, or autoclaved, preserved SARS-CoV-2 replication, however the antifungal present in the VTM was inactivated by autoclaving, suggesting that VTM prepared by autoclaving might be less useful where diagnostic samples are not refrigerated, or where transit time from sampling to diagnostic lab is longer than 1–2 days.

The next phase of the global response to the COVID-19 pandemic will be to more routinely isolate and sequence SARS-CoV-2 found in clinical samples, and to test whether they remain sensitive to the COVID-19 antivirals or plasma-derived (11) or laboratory-generated (12, 13) antibodies. After vaccination is implemented, SARS-CoV-2 that escape vaccine-induced immunity (14) will need to be studied and this will require viral culture. The data presented here suggests viral recovery will be optimized by the use of filter sterilized VTM.

Conclusions

The conservative preservation of SARS-CoV-2 in patient samples to enable viral culture will be required to fully understand why the growing list of COVID-19 vaccines or therapies fail. We showed that the method of CDC VTM preparation is critical to preserving the capacity of the virus to replicate. The optimal method to preserve viral culture used filter sterilization, while other methods supported nucleic acid-based diagnosis.

Abbreviations

VTM – viral transport medium

qPCR – quantitative detection of virus using the polymerase chain reaction

CDC – Centers for Diseases Control (US, based in Atlanta, GA, USA)

MPU – microbiological Media Production Unit of The University of Melbourne

SARS-CoV-2 – viral coronavirus agent causing Severe Acute Respiratory Syndrome, COVID-19

TCID₅₀ – tissue culture infectious dose 50%

CPE – cytopathic effect due to viral infection of tissue culture cells

Declarations

Ethics approvals

No ethics approvals were necessary for this work. Studies conducted under highly containment, i.e. the PC3 Laboratory of the Peter Doherty Institute, were per protocol, where all investigators were trained by accredited trainers.

Consent to publication

All the authors consent to the publication of the manuscript.

Availability of Data

The data contained within the manuscript is available for electronic transmission via the corresponding author.

Competing interests

There are no competing financial interests.

Funding

This work was funded by an NHMRC Program Grant ID1092262 supporting RAS and NW and an unrestricted grant from the A2 milk foundation supporting DJP.

Authors contributions

JM conducted the experiments, wrote and reviewed the paper, CF, EP and ET prepared the media and wrote and reviewed the paper, EB provided assistance with regulatory parameters and wrote and reviewed the paper, MS conducted the qPCR and reviewed the paper, DP supervised the experimental work, provided technical advice and wrote and reviewed the paper, NW analyzed the data, prepared the figures and wrote and reviewed the paper, and RS wrote and reviewed the paper.

Acknowledgements

The University of Melbourne acknowledges the support of Melbourne Health, through its Victorian Infectious Diseases Reference Laboratory at the Doherty Institute, in providing our laboratory with isolated SARS-CoV-2 material.

References

1. Druce J, Garcia K, Tran T, Papadakis G, Birch C. 2012. Evaluation of swabs, transport media, and specimen transport conditions for optimal detection of viruses by PCR. *J Clin Microbiol* 50:1064-5.
2. Williams E, Bond K, Isles N, Chong B, Johnson D, Druce J, Hoang T, Ballard SA, Hall V, Muhi S, Buising KL, Lim S, Strugnell D, Catton M, Irving LB, Howden BP, Bert E, Williamson DA. 2020. Pandemic printing: a novel 3D-printed swab for detecting SARS-CoV-2. *Med J Aust* doi:10.5694/mja2.50726.
3. Caly L, Druce J, Roberts J, Bond K, Tran T, Kostecki R, Yoga Y, Naughton W, Taiaroa G, Seemann T, Schultz MB, Howden BP, Korman TM, Lewin SR, Williamson DA, Catton MG. 2020. Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia. *Med J Aust* 212:459-462.
4. Lee JYH, Best N, McAuley J, Porter JL, Seemann T, Schultz MB, Sait M, Orlando N, Mercoulia K, Ballard SA, Druce J, Tran T, Catton MG, Pryor MJ, Cui HL, Luttick A, McDonald S, Greenhalgh A, Kwong JC, Sherry NL, Graham M, Hoang T, Herisse M, Pidot SJ, Williamson DA, Howden BP, Monk IR, Stinear TP. 2020. Validation of a single-step, single-tube reverse transcription loop-mediated isothermal amplification assay for rapid detection of SARS-CoV-2 RNA. *J Med Microbiol* doi:10.1099/jmm.0.001238.
5. Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. *American Journal of Hygiene* 27.
6. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brunink S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MP, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* 25.

7. McFee DRB. 2020. COVID-19: TESTING - Laboratory Testing - CDC Guidelines. Disease-a-Month doi:10.1016/j.disamonth.2020.101067:101067.
8. Radbel J, Jagpal S, Roy J, Brooks A, Tischfield J, Sheldon M, Bixby C, Witt D, Gennaro ML, Horton DB, Barrett ES, Carson JL, Panettieri RA, Jr., Blaser MJ. 2020. Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Is Comparable in Clinical Samples Preserved in Saline or Viral Transport Medium. *J Mol Diagn* 22:871-875.
9. Garnett L, Bello A, Tran KN, Audet J, Leung A, Schiffman Z, Griffin BD, Tailor N, Kobasa D, Strong JE. 2020. Comparison analysis of different swabs and transport mediums suitable for SARS-CoV-2 testing following shortages. *J Virol Methods* 285:113947.
10. Chapelier A, Desmadril M, Houee-Levin C. 2001. Gamma radiation effects on alpha-lactalbumin: structural modifications. *Can J Physiol Pharmacol* 79:154-7.
11. Zeng C, Evans JP, Pearson R, Qu P, Zheng YM, Robinson RT, Hall-Stoodley L, Yount J, Pannu S, Mallampalli RK, Saif L, Oltz E, Lozanski G, Liu SL. 2020. Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay. medRxiv doi:10.1101/2020.08.02.20166819.
12. Matthews DB. 2020. A cocktail of antibodies for COVID-19 therapy. *Nat Rev Immunol* doi:10.1038/s41577-020-00431-9.
13. Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, Jaconi S, Culap K, Zatta F, De Marco A, Peter A, Guarino B, Spreafico R, Cameroni E, Case JB, Chen RE, Havenar-Daughton C, Snell G, Telenti A, Virgin HW, Lanzavecchia A, Diamond MS, Fink K, Velesler D, Corti D. 2020. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature* 583:290-295.
14. Kaur SP, Gupta V. 2020. COVID-19 Vaccine: A comprehensive status report. *Virus Res* doi:10.1016/j.virusres.2020.198114:198114.

Figures




Figure 1

Recovery of replicative virus from VTM. VTM was prepared using three methods – filter sterilization, sterilization by autoclaving, or by gamma-irradiation. The VTM was inoculated with replicative virus then stored for various periods of time at 4°C (A) or RT (18-20°C, (B)) before viable virus was assayed using Vero cells, serially diluted VTM, where viral cytopathic effect (CPE) was examined. The virus recovered was expressed as TCID₅₀/mL. At each time point, the data for each method of preparation was compared using a Two ANOVA and Tukey post-test correction. A p<0.05 was considered significant (ns = not significant).